Drug intelligence / Profile preview

Omnicol

Development stage: Unknown
Lead developer: Pro Health Pharma Sweden
Modality: Small Molecules
Administration: Oral

Overview

**Omnicol** is an oral fixed-dose osmotic laxative product marketed by Pro Health Pharma for **chronic constipation** and for resolution of **faecal impaction** in adults, adolescents, and older people. Each sachet contains macrogol 3350 with sodium chloride, sodium hydrogen carbonate, and potassium chloride. Macrogol 3350 retains water in the intestinal lumen, softening stool and increasing stool volume to facilitate colonic propulsion and defecation.

Brand names: Omnicol

Beyond the preview

Go deeper on Omnicol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omnicol.

Explore the full profile